GeneNews nets $2m in financial boost:
This article was originally published in Clinica
Molecular diagnostics firm GeneNews (formerly known as ChondroGene) has secured $2m in financing through an agreement with an unnamed Asian biomedical consortium. The funds will be used to develop a new product for the early detection and management of prostate cancer. GeneNews' lead product is ColonSentry, a noninvasive test which aims to replace screening procedures such as colonoscopies, however the new funds are to be used solely for the development of the new product, which, if biomarkers are successfully identified, will be called ProstateSentry.